Guidelines for treatment of Helicobacter pylori in the East and West

References

• Cheng FC, Lam SK, Ong GB. Maximum acid output to graded doses of pentagastrin and its relation to parietal cell mass in Chinese patients with duodenal ulcer. Gut18, 827–832 (1997).
   Google Scholar
• Abdullahi M, Annibale B, Capoccia D et al. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes. Surg.18, 1450–1454 (2008).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Matsuo K, Ito H et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med.119, 217–224 (2006).
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C et al. Worldwide H. pylori antibiotic resistance: a systematic review. J. Gastrointestin. Liver Dis.19, 409–414 (2010).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut56, 772–781 (2007).
   PubMed Web of Science ®Google Scholar
• Di MF, Cavallaro LG, Scarpignato C. ‘Rescue’ therapies for the management of Helicobacter pylori infection. Dig. Dis.24, 113–130 (2006).
   PubMed Web of Science ®Google Scholar
• Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs64, 1893–1904 (2004).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr. Opin. Gastroenterol.26, 618–623 (2010).
   PubMed Web of Science ®Google Scholar
• Selgrad M, Kandulski A, Malfertheiner P. Helicobacter pylori: diagnosis and treatment. Curr. Opin. Gastroenterol.25, 549–556 (2009).
   PubMed Web of Science ®Google Scholar
• Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline – comparison of three 3-year studies. Arch. Iran. Med.13, 177–187 (2010).
   PubMed Web of Science ®Google Scholar
• Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Intern. Med.147, 553–562 (2007).
   PubMed Web of Science ®Google Scholar
• Haydee B, Flores A. Duration of proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Presented at: Digestive Disease Week 2010. New Orleans, LA, USA, 1–5 May 2010.
   Google Scholar
• Moayyedi P. Should triple therapy for Helicobacter pylori eradication be prescribed for 1 week or 2 weeks? Nat. Clin. Pract. Gastroenterol. Hepatol.4, 596–597 (2007).
   PubMedGoogle Scholar
• Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment. Pharmacol. Ther.20, 99–107 (2004).
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Leandro G, Di MF, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol.104, 3069–3079 (2009).
   PubMed Web of Science ®Google Scholar
• Sirimontaporn N, Thong-Ngam D, Tumwasorn S, Mahachai V. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am. J. Gastroenterol.105, 1071–1075 (2010).
   PubMed Web of Science ®Google Scholar
• Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for Helicobacter pylori eradication: the time is now! Therap. Adv. Gastroenterol.2, 317–322 (2009).
   PubMedGoogle Scholar
• Romano M, Cuomo A, Gravina AG et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut59, 1465–1470 (2010).
   PubMed Web of Science ®Google Scholar
• Mahachai V, Sirimontaporn N, Tumwasorn S, Thong-Ngam D, Vilaichone RK. Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J. Gastroenterol. Hepatol.26, 825–828 (2011).
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut59, 1143–1153 (2010).
   PubMed Web of Science ®Google Scholar
• Wu DC, Hsu PI, Wu JY et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin. Gastroenterol. Hepatol.8, 36–41 (2010).
   PubMed Web of Science ®Google Scholar
• Okada M, Nishimura H, Kawashima M et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment. Pharmacol. Ther.13, 769–774 (1999).
   PubMed Web of Science ®Google Scholar
• Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter14, 109–118 (2009).
   PubMed Web of Science ®Google Scholar
• Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol. Ther.18, 543–544 (2003).
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol.98, 562–567 (2003).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier JC et al.Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, Phase 3 trial. Lancet377, 905–913 (2011).
   PubMed Web of Science ®Google Scholar
• Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am. J. Gastroenterol.105, 65–73 (2010).
   PubMed Web of Science ®Google Scholar
• Sun Q, Liang X, Zheng Q et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter15, 233–238 (2010).
   PubMed Web of Science ®Google Scholar
• Dore MP, Graham DY, Mele R et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am. J. Gastroenterol.97, 857–860 (2002).
   PubMed Web of Science ®Google Scholar
• Lin CK, Hsu PI, Lai KH et al. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J. Clin. Gastroenterol.34, 547–551 (2002).
   PubMed Web of Science ®Google Scholar
• Liou JM, Lin JT, Chang CY et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut59, 572–578 (2010).
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Gisbert JP. Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. Gut DOI:10.1136/gut.2010.233015 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Zullo A, De Francesco V, Vaira D. Sequential therapy for Helicobacter pylori eradication: is levofloxacin better? Gut DOI:10.1136/gut.2010.231233 (2010) (Epub ahead of print).
   Google Scholar
• Nista EC, Candelli M, Zocco MA et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther.21, 1241–1247 (2005).
   PubMed Web of Science ®Google Scholar
• Yoon H, Kim N, Lee BH et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter14, 77–85 (2009).
   PubMed Web of Science ®Google Scholar
• Bago J, Majstorovic K, Belosic-Halle Z et al. Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days moxifloxacin based therapy for the eradication: a randomized controlled trial. Ann. Clin. Microbiol. Antimicrob.9, 13 (2010).
   PubMedGoogle Scholar
• Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig. Liver Dis.42, 110–114 (2010).
   PubMedGoogle Scholar
• Kang JM, Kim N, Lee DH et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter12, 623–628 (2007).
   PubMed Web of Science ®Google Scholar
• Miehlke S, Schneider-Brachert W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter13, 69–74 (2008).
   PubMed Web of Science ®Google Scholar
• Fock KM, Ang TL Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J. Gastroenterol. Hepatol.25, 479–486 (2010).
   PubMed Web of Science ®Google Scholar
• Graham DY, Adam E, Reddy GT et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig. Dis. Sci.36, 1084–1088 (1991).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Blaser MJ The epidemiology of Helicobacter pylori infection. Epidemiol. Rev.13, 42–59 (1991).
   PubMed Web of Science ®Google Scholar
• Asaka M, Kato M, Takahashi S et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter15, 1–20 (2010).
   PubMed Web of Science ®Google Scholar
• Bourke B, Ceponis P, Chiba N et al. Canadian Helicobacter Study Group Consensus Conference: update on the approach to Helicobacter pylori infection in children and adolescents – an evidence-based evaluation. Can. J. Gastroenterol.19, 399–408 (2005).
   PubMed Web of Science ®Google Scholar
• Caselli M, Zullo A, Maconi G et al. “Cervia II Working Group Report 2006”: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig. Liver Dis.39, 782–789 (2007).
   PubMedGoogle Scholar
• Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol.102, 1808–1825 (2007).
   PubMed Web of Science ®Google Scholar
• Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-guideline “Helicobacter pylori and gastroduodenal ulcer disease” of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021/001. Z. Gastroenterol.47, 1230–1263 (2009).
   PubMed Web of Science ®Google Scholar
• Fock KM, Katelaris P, Sugano K et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol.24, 1587–1600 (2009).
   PubMed Web of Science ®Google Scholar
• Megraud F. Helicobacter pylori and antibiotic resistance. Gut56, 1502 (2007).
   PubMed Web of Science ®Google Scholar
• Cambau E, Allerheiligen V, Coulon C et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J. Clin. Microbiol.47, 3600–3607 (2009).
   PubMed Web of Science ®Google Scholar
• Czinn SJ, Blanchard T. Vaccinating against Helicobacter pylori infection. Nat. Rev. Gastroenterol. Hepatol.8, 133–140 (2011).
   PubMed Web of Science ®Google Scholar
• Del GG, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert. Rev. Vaccines8, 1037–1049 (2009).
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology135, 787–795 (2008).
   PubMed Web of Science ®Google Scholar
• Wolle K, Nilius M, Leodolter A, Muller WA, Malfertheiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur. J. Clin. Microbiol. Infect. Dis.17, 519–521 (1998).
   PubMed Web of Science ®Google Scholar
• Storskrubb T, Aro P, Ronkainen J et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter11, 224–230 (2006).
   PubMed Web of Science ®Google Scholar
• Zullo A, Perna F, Hassan C et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment. Pharmacol. Ther.25, 1429–1434 (2007).
   PubMed Web of Science ®Google Scholar
• Boyanova L, Nikolov R, Lazarova E et al. Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J. Med. Microbiol.55, 65–68 (2006).
   PubMed Web of Science ®Google Scholar
• Dzierzanowska-Fangrat K, Rozynek E, Celinska-Cedro D et al. Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int. J. Antimicrob. Agents26, 230–234 (2005).
   PubMed Web of Science ®Google Scholar
• Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill.12, E3–E4 (2007).
   PubMedGoogle Scholar
• Vallejos C, Garrido L, Caceres D et al. Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients. Rev. Med. Chil.135, 287–293 (2007).
   PubMed Web of Science ®Google Scholar
• Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am. J. Gastroenterol.93, 1432–1435 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng H, Hu FL, Li J. Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens. Zhonghua Yi Xue Za Zhi86, 2679–2682 (2006).
   PubMedGoogle Scholar
• Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol.45, 4006–4010 (2007).
   PubMed Web of Science ®Google Scholar
• Datta S, Chattopadhyay S, Patra R et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment. Pharmacol. Ther.22, 51–57 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmad N, Zakaria WR, Abdullah SA, Mohamed R. Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. World J. Gastroenterol.15, 3161–3165 (2009).
   PubMed Web of Science ®Google Scholar
• Kim N, Kim JM, Kim CH et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J. Clin. Gastroenterol.40, 683–687 (2006).
   PubMed Web of Science ®Google Scholar
• Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J. Gastroenterol. Hepatol.24, 1230–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Asrat D, Kassa E, Mengistu Y, Nilsson I, Wadstrom T. Antimicrobial susceptibility pattern of Helicobacter pylori strains isolated from adult dyspeptic patients in Tikur Anbassa University Hospital, Addis Ababa, Ethiopia. Ethiop. Med. J.42, 79–85 (2004).
   PubMedGoogle Scholar
• Gao W, Cheng H, Hu F et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter15, 460–466 (2010).
   PubMed Web of Science ®Google Scholar